Drug products: Amiloferm®, Amiloferm® mite, Amilorid HCL, Amilorid Mylan, Amiloride, Amiloride Hydrochloride, Midamor, Modamide, Moduretic, Moduretic®, Moduretic® mite, Normorix, Normorix mite, Sparkal®, Sparkal® mite
ATC code: C03DB01, C03EA01
Substances: amiloride, amiloride hydrochloride anhydrous, amiloride hydrochloride dihydrate
Controlled studies on differences between men and women on effect, safety and pharmacokinetics for amiloride are lacking.
No studies with a clinically relevant sex analysis regarding the pharmacokinetics or dosing of amiloride have been found.
No studies with a clinically relevant sex analysis regarding the dosing of amiloride have been found.
No conclusive studies with a clinically relevant sex analysis regarding the effects of amiloride have been found.
No studies with a clinically relevant sex analysis regarding adverse effects of amiloride have been found.
Regarding teratogenic aspects, please consult Janusmed Drugs and Birth Defects (in Swedish, Janusmed fosterpåverkan).
A large British randomized, placebo-controlled, single-blind trial compared treatment with hydrochlorothiazide plus amiloride and atenolol in hypertensive older adults (in total 1836 men, 2560 women). Number of deaths from cancer among patients taking diuretic was higher in men than women (0.7% of men 0.3% of women on diuretics compared to 0.5% of men and 0.6% of women with placebo) . These results have unclear relevance today. The cancer mortality rates in UK have fallen by 19% for women and 29% for men between 1990-2016 .
Date of litterature search: 2019-03-11
Reviewed by: Mia von Euler
Approved by: Karin Schenck-Gustafsson